c-Jun Antibody (Phospho-Ser243), pAb, Rabbit
- Known as:
- c-Jun Antibody (Phospho-Ser243), pAb, Rabbit
- Catalog number:
- A00237-100
- Product Quantity:
- 100,0μg
- Category:
- -
- Supplier:
- Genscript
- Gene target:
- c-Jun Antibody (Phospho-Ser243) pAb Rabbit
Related products to: c-Jun Antibody (Phospho-Ser243), pAb, Rabbit
Related articles to: c-Jun Antibody (Phospho-Ser243), pAb, Rabbit
- Chronic biliary injury drives liver fibrosis, yet mechanisms governing injury resolution and hepatocyte regeneration remain unclear. Periplakin (PPL), a cholangiocyte-enriched cytoskeletal linker, is upregulated during biliary injury, but its functional contribution to fibrosis and repair has not been defined. - Source: PubMed
Xu MeiyiningHuang YunJiang KefengZhang LichaoHuang WanxianShen JiaLei JunxiaHuang YanSun XiWu Zhongdao - Despite abundant evidence that the admission of an infant to a neonatal intensive care unit (NICU) is a highly stressful and potentially traumatic experience for both infants and parents, few psychosocial interventions target the needs of parents of NICU infants. In particular, interventions supporting parents beyond the initial medical crisis are notably lacking. Relational savoring (RS) is a brief, positive psychology intervention that attunes one's focus to moments of positive connectedness within their relationships, including parent-child relationships. While the benefits of RS for parent-child dyads are well documented, its efficacy has not been evaluated in parent-child dyads facing significant relational stressors, such as those experienced in post-NICU contexts. Using a randomized controlled design, this study tests the effects of RS compared to a neutral control in 240 post-NICU parents in the United States. Parents reported on their closeness to their child, parental emotional well-being, and parental satisfaction before and after the intervention, as well as their history of perinatal loss and stress. Results of multilevel models suggest that, relative to a neutral control task, parents assigned to the RS intervention group exhibited significantly greater increases in feelings of closeness to their child, parenting satisfaction, and parental emotional well-being. Interestingly, the reduction in negative affect pre- to post-intervention was more pronounced for parents with a history of miscarriage, stillbirth, child loss, and/or fertility difficulties. These findings suggest that RS may represent a scalable intervention to support parent-child relationships and parental well-being in the post-NICU period, particularly for parents with prior perinatal loss and stress. - Source: PubMed
Lord Kaitlin MBoyce HaLiFortier Michelle ASzepsenwol OhadZamir OsnatTan PatriciaHajal NastassiaMogil CatherineBorelli Jessica L - Hepatitis B surface antigen (HBsAg) loss is associated with improved clinical outcomes in patients with chronic hepatitis B virus (HBV) infection based on studies predominantly in Asian populations. We assessed real-world associations between HBsAg loss and long-term clinical outcomes in a diverse US population with chronic HBV infection. This retrospective cohort study (January 2012-December 2019) used Optum electronic health records data from patients with chronic HBV infection, identified via diagnosis codes or laboratory assessments. Patients with advanced liver disease and hepatitis C, hepatitis D or HIV co-infection at baseline were excluded. Associations between HBsAg loss, as a proxy of functional cure, and clinical outcomes were assessed using doubly robust inverse probability of treatment-weighted Cox proportional hazards models. In total, 15,760 patients with chronic HBV infection were included; 5.6% were receiving stable antiviral treatment. Overall, 4.2% (n = 667) experienced HBsAg loss across the study period. HBsAg loss was associated with an 89% and 62% reduced risk of hepatocellular carcinoma (HCC; adjusted hazard ratio [aHR]: 0.11, 95% CI: 0.01-0.76) and all-cause mortality (ACM; aHR: 0.38, 95% CI: 0.20-0.74), respectively. Risks of compensated cirrhosis (aHR: 0.84, 95% CI: 0.52-1.35) and decompensated liver disease (aHR: 0.74, 95% CI: 0.37-1.48) were lower after HBsAg loss, but did not reach significance. In this large, diverse population of patients with chronic HBV infection without advanced liver disease, HBsAg loss was associated with reduced risks of HCC and ACM compared with those without HBsAg loss. - Source: PubMed
Drysdale MyriamChang RoseWang ShuangCoutinho AnnaGielen VeraMan TheoSong RuiDuh Mei ShengKhalili MandanaTheodore Dickens - - Source: PubMed
Publication date: 2026/05/16
Britton Carolina - Ongoing monitoring of hepatitis C virus (HCV) and HIV incidence among people who inject drugs (PWID) is important for epidemic control and assessing progress towards disease elimination. We estimated trends in HIV and HCV infection incidence in a community-based cohort of PWID in Montreal, Canada. Data from March 2011 to March 2025 were drawn from the HEPCO study of PWID aged ≥ 18 years and living in Montreal. Participants with at least two visits were included in analyses. We used a random point approach to estimate the date of each infection event, imputing each date 1000 times, and Rubin's rules to pool incidence rates and 95% CIs across imputations. A total of 743 participants contributed to HCV analyses, with 152 infection events and incidence of 6.47 per 100 person-years (p-y) (95% CI 6.46-6.49). Incidence peaked in 2013 and declined to 2019 before increasing again post-pandemic. There were 61 primary HCV infection events (incidence: 6.15 per 100 p-y; 95% CI 4.79-7.90) and 91 reinfection events (incidence: 6.71 per 100 p-y; 95% CI 6.69-6.73). A total of 836 participants contributed to HIV analysis, with only eight infections over 3089.89 p-y (incidence: 0.26 per 100 p-y; 95% CI 0.13-0.52). Declining HCV incidence among PWID in Montreal may have reversed, but limited data collection during the years 2020-2021 complicates interpretation. HIV incidence was persistently low. HCV incidence remains above World Health Organization elimination targets, highlighting the need for sustained investment in prevention and linkage to care for PWID. - Source: PubMed
Kleiner Bluma BlakeMeconnen MilcaAzar MarleineMinoyan NanorZang GengArtenie AdelinaMartel-Laferrière ValérieJutras-Aswad DidierBruneau JulieLarney Sarah